Home » Stocks » LRMR

Larimar Therapeutics, Inc. (LRMR)

Stock Price: $8.00 USD -0.04 (-0.44%)
Updated Jun 16, 2021 3:35 PM EDT - Market open
Market Cap 124.94M
Revenue (ttm) n/a
Net Income (ttm) -47.90M
Shares Out 16.00M
EPS (ttm) -3.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $8.00
Previous Close $8.03
Change ($) -0.04
Change (%) -0.44%
Day's Open 8.04
Day's Range 7.91 - 8.18
Day's Volume 44,553
52-Week Range 7.00 - 25.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...

5 days ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investo...

1 week ago - Newsfile Corp

The FDA has instituted a clinical hold on Larimar Therapeutics Inc's (NASDAQ: LRMR) CTI-1601 clinical program as a treatment for Friedreich's Ataxia (FA), a neurodegenerative movement disorder. The clin...

3 weeks ago - Benzinga

BALA CYNWYD, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 weeks ago - GlobeNewsWire

Larimar Therapeutics Inc (NASDAQ: LRMR) has executed a securities purchase agreement to raise gross proceeds of approximately $95 million in a private placement. The proceeds will be used to support the...

3 weeks ago - Benzinga

BALA CYNWYD, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 weeks ago - GlobeNewsWire

BALA CYNWYD, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

3 weeks ago - GlobeNewsWire

Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading lower despite announcing positive topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich...

1 month ago - Benzinga

Larimar Therapeutics Inc (NASDAQ: LRMR) has announced topline data from its Phase 1 multiple ascending dose trial evaluating CTI-1601 as a treatment for Friedreich's Ataxia (FA). FA is a genetic, progre...

1 month ago - Benzinga

BALA CYNWYD, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich's ataxia ...

1 month ago - GlobeNewsWire

- Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET

1 month ago - GlobeNewsWire

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused i...

Other stocks mentioned: ZFGN
1 year ago - GlobeNewsWire

Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the commercializa...

Other stocks mentioned: ZFGN
1 year ago - Benzinga

Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant near-term r...

Other stocks mentioned: ZFGN
1 year ago - GlobeNewsWire

Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.

Other stocks mentioned: ZFGN
2 years ago - Benzinga

Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndrome.

Other stocks mentioned: ZFGN
2 years ago - Benzinga

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
LRMR
Full Company Profile

Financial Performance

Financial Statements